MedTrace Logo

To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart

NCT01222442 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-02-16

No results posted yet for this study

Summary

The purpose of this research study is to evaluate the effect of AZD3199 on the electrical activity of the heart. The effect of AZD3199 will be compared to a licensed antibiotic (moxifloxacin). Moxifloxacin effects on the electrical activity of the heart are well known. Safety and tolerability of AZD3199 and how much AZD3199 enters the blood circulation will also be assessed.

Conditions

Interventions

DRUG

AZD3199

Single dose, oral inhalation

DRUG

Moxifloxacin

Single dose, oral encapsulated tablet

OTHER

Placebo comparator

Single dose, oral inhalation

Sponsors & Collaborators

Principal Investigators

  • Carin Jorup, MD · AstraZeneca R&D, Lund, Sweden

  • Leonard Siew, MB CHB · Quintiles Drug Research Unit at Guy's Hospital, London

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01222442 on ClinicalTrials.gov